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Aging is an intricate phenomenon characterized by progressive decline in physiological functions and increase in mortality that
is often accompanied by many pathological diseases. Although aging is almost universally conserved among all organisms, the
underlying molecular mechanisms of aging remain largely elusive. Many theories of aging have been proposed, including the free-
radical and mitochondrial theories of aging. Both theories speculate that cumulative damage to mitochondria and mitochondrial
DNA (mtDNA) caused by reactive oxygen species (ROS) is one of the causes of aging. Oxidative damage aﬀects replication and
transcription of mtDNA and results in a decline in mitochondrial function which in turn leads to enhanced ROS production
and further damage to mtDNA. In this paper, we will present the current understanding of the interplay between ROS and
mitochondria and will discuss their potential impact on aging and age-related diseases.
1. Introduction
The fundamental manifestation of the aging process is a
progressive decline in the functional maintenance of tissue
homeostasis and an increasing propensity to degenerative
diseases and death [1]. It has attracted significant interest
to study the underlying mechanisms of aging, and many
theories have been put forward to explain the phenomenon
of aging. There is an emerging consensus that aging is a
multifactorial process, which is genetically determined and
influenced epigenetically by environment [2]. Most aging
theories postulate a single physiological cause of aging, and
likely these theories are correct to a certain degree and in
certain aspects of aging.
Reactive oxygen species (ROS) are highly reactive mol-
ecules that consist of a number of diverse chemical species
including superoxide anion (O2
−), hydroxyl radical (·OH),
and hydrogen peroxide (H2O2). Because of their potential
to cause oxidative deterioration of DNA, protein, and
lipid, ROS have been implicated as one of the causative
factors of aging [3]. As ROS are generated mainly as by-
products of mitochondrial respiration, mitochondria are
thought to be the primary target of oxidative damage and
play an important role in aging. Emerging evidence has
linked mitochondrial dysfunction to a variety of age-related
diseases, including neurodegenerative diseases and cancer.
Details of the precise relationship between ROS-induced
damage, mitochondrial dysfunction, and aging remain to be
elucidated.
2. ROS and Aging
2.1. ROS, Oxidative Damage, and Cellular Signaling. There
are several sources of ROS within a cell. ROS are generated
as by-products of aerobic respiration and various other
catabolic and anabolic processes [4]. Mitochondria are
the major producer of ROS in cells, and the bulk of
mitochondrial ROS is generated at the electron transport
chain [5, 6]. Electrons leak from the electron transport chain
directly to oxygen, producing short-lived free radicals such as
superoxide anion (O2
−) [7, 8]. O2− can be converted to non-
radical derivatives such as hydrogen peroxide (H2O2) either
spontaneously or catalyzed by superoxide dismutase (SOD)
[9–13]. H2O2 is relatively stable and membrane permeable.
It can be diﬀused within the cell and be removed by cytosolic
antioxidant systems such as catalase, glutathione peroxidase,
and thioredoxin peroxidase [14, 15]. In addition to being
generated during cellular metabolism in mitochondria, ROS
can be produced in response to diﬀerent environmental
stimuli such as growth factors, inflammatory cytokines, ion-
izing radiation, UV, chemical oxidants, chemotherapeutics,
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hyperoxia, toxins, and transition metals [16–26]. Other than
mitochondrial respiration, a number of cytosolic enzymes
are able to generate ROS [27]. The nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases are a group of
plasma membrane-associated enzymes found in a variety
of cell types [28]. The function of NADPH oxidases is
to produce superoxide from oxygen using electrons from
NADPH [29].
Once they are produced, ROS react with lipids, pro-
teins, and nucleic acids causing oxidative damage to these
macromolecules [30–34]. ROS readily attack DNA and
generate a variety of DNA lesions, such as oxidized DNA
bases, abasic sites, and DNA strand breaks, which ulti-
mately lead to genomic instability [35]. 7,8-dihydro-8-oxo-
deoxyguanosine (8-oxo-dG) is one of the most abundant
and well-characterized DNA lesions caused by ROS [36].
It is a highly mutagenic lesion that results in G : C to T : A
transversions [37]. To limit the cellular damage caused by
ROS, mammalian cells have evolved a number of sophis-
ticated defense mechanisms. ROS-generated DNA lesions
are repaired mainly by base excision repair as well as other
DNA repair pathways including nucleotide excision repair,
double-strand break repair, and mismatch repair [38–40].
In addition, the damaging eﬀects of ROS can be neutralized
via elevated antioxidant defense, which includes superoxide
dismutase, catalase, and glutathione peroxidase to scavenge
ROS to nontoxic forms [41].
Intracellular ROS are normally maintained at low but
measurable level within a narrow range, which is regulated
by the balance between the rate of production and the
rate of scavenging by various antioxidants [42]. ROS, at
low level under normal conditions, is found to act as
signaling molecules in many physiological processes, includ-
ing redox homeostasis and cellular signal transduction [7].
By activating proteins such as tyrosine kinases, mitogen-
activated protein kinases, or Ras proteins, ROS are important
mediators of signal transduction pathways [7]. Dependent
on cell types, ROS have been found to function as signaling
molecules in cell proliferation [43], cellular senescence [44],
or cell death [45, 46]. The divergent eﬀects of ROS on
many cellular processes suggest that ROS are not merely
detrimental byproducts, but also generated purposefully to
mediate a variety of signaling pathways.
2.2. The Free Radical Theory of Aging. The free radical theory
of aging proposed by Denham Harman more than fifty years
ago postulates that aging results from the accumulation of
deleterious eﬀects caused by free radicals, and the ability
of an organism to cope with cellular damage induced by
ROS plays an important role in determining organismal
lifespan [3]. In agreement with this theory, increased ROS
production by mitochondria and increased 8-oxo-dG con-
tent in the mtDNA are frequently detected in aged tissues
[40, 47–50], suggesting that progressive accumulation of
oxidative DNA damage is a contributory factor to the aging
process. Consistently, many studies have found that increased
oxidative damage in cells is associated with aging [51–53].
Furthermore, genetic studies in worm, fly, and mouse have
linked enhanced stress resistance or reduced free radical
production with increased lifespan [27]. Mutant strains of
C. elegans that are resistant to oxidative stress have extended
lifespan, whereas those more susceptible to free radicals have
shortened lifespan [54, 55]. Mice lacking the antioxidant
enzyme superoxide dismutase 1 (SOD1) exhibit a 30%
decrease in life expectancy [56]. Conversely, simultaneous
overexpression of SOD1 and catalase extends lifespan in
Drosophila [57]. Small synthetic mimetics of SOD/catalase
increase lifespan in C. elegans [58], while treatment of
antioxidant drugs in mice increases the median lifespan
up to 25% [59, 60]. Further supporting this hypothesis,
mice lacking Ogg1 and Myh, two enzymes of the base
excision repair pathway that repairs oxidative DNA damage,
show a 50% reduction in life expectancy [61]. Collectively,
these studies demonstrate that interplay between ROS and
protective antioxidant responses is an important factor in
determining aging and lifespan.
Despite a large body of evidence supporting the role of
ROS in aging, the free radical theory of aging faces some
challenges [62]. Mice heterozygous for superoxide dismu-
tase 2 (Sod2+/−) have reduced manganese SOD (MnSOD)
activity, increased oxidative damage, but normal lifespan
[63]. Overexpression of antioxidant enzymes in mice, such
as SOD1 or catalase, does not extend lifespan [64, 65].
The median lifespan of mice heterozygous of glutathione
peroxidase 4 (Gpx4+/−), an antioxidant defense enzyme
that plays an important role in detoxification of oxidative
damage to membrane lipids, is significantly longer than
that of wild-type mice, even though Gpx4+/− mice show
increased sensitivity to oxidative stress-induced apoptosis
[66]. Studies of long-lived rodents also do not find a
convincing correlation between level of oxidative damage
and aging [67]. Furthermore, pharmacologic intervention
with antioxidants in humans and mice has little eﬀect on
prolonging lifespan [68–70]. More investigations are clearly
needed to clarify the discrepancy in the role of ROS and
antioxidant enzymes in aging among diﬀerent species and to
understand the precise role that free radicals play in aging.
2.3. ROS and Senescence. Senescence, a process in which
normal somatic cells enter an irreversible growth arrest
after a finite number of cell divisions [71], is thought
to contribute to organismal aging [72–74]. Senescent cells
are associated with high level of intracellular ROS and
accumulated oxidative damage to DNA and protein [75–
77]. In contrast, immortal cells suﬀer less oxidative damage
and are more resistant to the deleterious eﬀects of H2O2
than primary cells [78]. Increasing intracellular oxidants
by altering ambient oxygen concentrations or lowering
antioxidant levels accelerates the onset of senescence, while
lowering ambient oxygen or increasing ROS scavenging
delays senescence [76, 78–81].
Telomere shortening is considered as the major cause of
replicative senescence [82, 83]. It has been reported that the
rate of telomere shortening is directly related to the cellular
level of oxidative stress [84]. Telomere shortening is signifi-
cantly increased under mild oxidative stress as compared to
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that observed under normal conditions, whereas overexpres-
sion of the extracellular SOD in human fibroblasts decreases
the peroxide content and the rate of telomere shortening
[79]. ROS can aﬀect telomere maintenance at multiple
levels. The presence of 8-oxoguanine (8-oxoG), an oxidative
derivative of guanine, in telomeric repeat-containing DNA
oligonucleotides has been shown to impair the formation
of intramolecular G quadruplexes and reduces the aﬃnity
of telomeric DNA for telomerase, thereby interfering with
telomerase-mediated extension of single-stranded telomeric
DNA [85]. ROS also aﬀect telomeres indirectly through
their interaction with the catalytic subunit of telomerase,
telomerase reverse transcriptase (TERT). Increased intra-
cellular ROS lead to loss of TERT activity, whereas ROS
scavengers such as N-acetylcysteine (NAC) block ROS-
mediated reduction of TERT activity and delay the onset
of cellular senescence [86]. Furthermore, the presence of 8-
oxoG in the telomeric sequence reduces the binding aﬃnity
of TRF1 and TRF2 to telomeres [87]. TRF1 and TRF2
are components of the telomere-capping shelterin complex
that protects the integrity of telomeres [88]. In addition,
ROS-induced DNA damage elicits a DNA damage response,
leading to the activation of p53 [89], a critical regulator of
senescence. It has been shown that p53 transactivates E3
ubiquitin ligase Siah1, which in turnmediates ubiquitination
and degradation of TRF2. Consequently, knockdown of
Siah1 expression stabilizes TRF2 and delays the onset of
replicative senescence [90]. The p53-Siah1-TRF2 regulatory
axis places p53 both downstream and upstream of DNA
damage signaling initiated by telomere dysfunction. By
regulating telomere maintenance or integrity directly or
indirectly, ROS plays a critical role in senescence.
2.4. ROS and Stem Cell Aging. Tissue-specific or adult stem
cells, which are capable of self-renewal and diﬀerentiation,
are essential for the normal homeostatic maintenance and
regenerative repair of tissues throughout the lifetime of an
organism. The self-renewal ability of stem cells is known to
decline with advancing age [91–94], suggesting that decline
in stem cell function plays a central role in aging. Increasing
evidence suggests that dysregulated formation of ROS may
drive stem and progenitor cells into premature senescence
and therefore impede normal tissue homeostasis.
Genetic studies of mice deficient in genes implicated in
ROS regulation indicate that elevated level of ROS within
the stem cell compartments leads to a rapid decline in stem
cell self-renewal [95–98]. Deletion of Ataxia telangiectasia
mutated (ATM) kinase results in increased ROS level in
hematopoietic stem cell (HSC) population in aged mice,
which correlates with a rapid decline in HSC number
and function [95]. When Atm−/− mice are treated with
antioxidants, the defect in stem cell self-renewal is rescued
[95], suggesting that high level of ROS causes the decline
in stem cell function. Furthermore, deficiency in telomerase
reverse transcriptase (TERT) accelerates the progression
of aging, resulting in an even shorter lifespan in Atm−/−
mice accompanied by increased senescence in hematopoietic
tissues and decreased stem cell activity [99]. These TERT-
deficient HSCs are also sensitive to ROS-induced apoptosis,
suggesting another possible cause of stem cell impairment
during aging [99]. Similarly, defect in HSC number and
activity accompanied by increased accumulation of ROS
is observed in mice lacking three members of Forkhead
box O-class (FoxO) [96–98]. Increased level of ROS in
FoxO3-null myeloid progenitors leads to hyperproliferation
through activation of the AKT/mTOR signaling pathway,
and ultimately premature exhaustion of progenitors [100].
Mice carrying a mutation in inner mitochondrial membrane
peptidase 2-like (Immp2l) gene, which is required to process
signal peptide of mitochondrial cytochrome c1 and glycerol
phosphate dehydrogenase 2, exhibit an early onset of aging
phenotypes, including premature loss of fat [101]. Elevated
mitochondrial ROS level in the Immp2l mutant mice leads to
impaired self-renewal of adipose progenitor cells, suggesting
that ROS-induced damage to adult stem cells is the driving
force of accelerated aging in these mice [101]. Further
supporting this notion, intracellular level of ROS is found
to correlate with the long-term self-renewal ability of HSCs
in mouse [102]. HSCs with high level of ROS show a
decreased ability of long-term self-renewal, and treatment
of antioxidant NAC is able to restore the functional activity
of HSCs with high level of ROS [102]. Taken together, these
studies suggest that ROS play an important role in stem cell
aging.
ROS-generated DNA lesions are repaired by several DNA
repair pathways including base excision repair, nucleotide
excision repair, double-strand break repair, and mismatch
repair [38–40]. Endogenous DNA damage accumulates
with age in HSCs in mouse. HSCs in mice deficient in
DNA repair pathways, including nucleotide excision repair,
telomere maintenance, and nonhomologous end-joining,
exhibit increased sensitivity to the detrimental eﬀect of ROS,
diminished self-renewal and functional exhaustion with age
[103]. These data support the notion that accumulated DNA
damage is one of the principal mechanisms underlying age-
dependent stem cell decline.
3. Mitochondria and Aging
3.1. The Mitochondrial Theory of Aging. Because mitochon-
dria are the major producer of ROS in mammalian cells,
the close proximity to ROS places mitochondrial DNA
(mtDNA) prone to oxidative damage [104]. Consistently,
many studies have shown that 8-oxo-dG, one of the common
oxidative lesions, is detected at higher level in mtDNA than
nuclear DNA, suggesting that mtDNA is more susceptible to
oxidative damage [52, 105–113]. As both the major producer
and primary target of ROS, mitochondria are thought to
play an important role in aging. The mitochondrial theory
of aging, extended from the free radical theory, proposes
that oxidative damage generated during oxidative phospho-
rylation of mitochondrial macromolecules such as mtDNA,
proteins, or lipids is responsible for aging [114]. As mtDNA
encodes essential components of oxidative phosphorylation
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and protein synthesis machinery [115], oxidative damage-
induced mtDNA mutations that impair either the assembly
or the function of the respiratory chain will in turn trigger
further accumulation of ROS, which results in a vicious cycle
leading to energy depletion in the cell and ultimately cell
death [104, 114, 116–118].
As mitochondria play a critical role in regulation of
apoptosis, which is implicated in the aging process [119],
age-related mitochondrial oxidative stress may contribute
to apoptosis upon aging. The activation of the perme-
ability transition pore in mitochondria, which is believed
to play a critical role in cell necrosis and apoptosis, is
enhanced in spleen, brain, and liver of aged mice [120, 121].
Moreover, mitochondrial adenine nucleotide translocase, a
component of the permeability transition pore, exhibits an
age-associated increase of oxidative modification in male
houseflies [122]. Such selective oxidative modification may
cause the cells more vulnerable to apoptotic inducers [123].
Thus, mitochondria appear to influence the aging process via
modifying the regulatory machinery of apoptosis.
Mice expressing proof reading-deficient mitochondrial
DNA polymerase show a consistent increase in mtDNA
mutations, premature onset of the aging phenotypes and
reduced lifespan [124, 125], suggesting a critical link between
mitochondria and aging. Interestingly, ROS production in
these mice is not increased [124, 125]. Similarly, mice
expressing proof reading-deficient mitochondrial DNA poly-
merase specifically in heart show accumulation of mutations
in mtDNA and develop cardiomyopathy, but oxidative stress
in the transgenic heart is not increased, indicating that
oxidative stress is not an obligate mediator of diseases
provoked by mtDNA mutations [126]. More studies are
required to further clarify the consequence of oxidative stress
and mitochondrial dysfunction in aging.
3.2. Age-Associated Changes of Mitochondria. Mitochondrial
genome encodes proteins required for oxidative phospho-
rylation and ATP synthesis, and RNAs needed for mito-
chondrial protein translation [115]. The mtDNA is densely
packed with genes and only contains one noncoding region
called the displacement loop (D-loop) [127]. The D-loop
is important for mtDNA replication and transcription and
has been extensively studied for the presence of age-related
mutations [115]. Age-dependent accumulation of point
mutations within the D-loop has been reported in various
types of cells and tissues, including skin and muscle [128–
132]. In addition to point mutations, deletions of mtDNA
are detected at higher frequency in aged human and animal
tissues [133–145]. Replication is thought to be the likely
mechanism leading to the formation of mtDNA deletions
[146–148], but recent studies suggest that mtDNA deletions
may be generated during repair of damaged mtDNA rather
than during replication [149]. It is thought that repair
of oxidative damage to mtDNA accumulated during aging
leads to generation of double-strand breaks [149], with
single-strand regions free to anneal with microhomolo-
gous sequences on other single-stranded mtDNA or within
the noncoding region [150]. Subsequent repair, ligation
and degradation of the remaining exposed single strands
would result in the formation of an intact mitochondrial
genome harboring a deletion [149]. Whether and how
exactly mutations and deletions of mtDNA cause the aging
phenotypes are not clear. Among mtDNA deletions during
aging, especially in postmitotic tissues like muscle and brain,
the most common one is a 4977-bp deletion [151–153].
The frequency of this deletion increases in brain, heart, and
skeletal muscle with age, although the increase varies in
diﬀerent tissues of the same individual [154], or even in
diﬀerent regions of the same tissue [134, 136, 137]. This
deletion occurs in a region encoding subunits of the NADH
dehydrogenase, cytochrome c oxidase, and ATP synthase
[155]. Whether deletion of these genes plays a causative
role in the development of aging phenotypes remains to be
determined.
In addition to age-associated increase of mtDNA muta-
tions and deletions, the abundance of mtDNA also declines
with age in various tissues of human and rodent [156–
158]. For instance, in a large group of healthy men and
women aged from 18 to 89 years, mtDNA and mRNA
abundance is found to decline with advancing age in the
vastus lateralis muscle. Furthermore, abundance of mtDNA
correlates with the rate of mitochondrial ATP production
[158], suggesting that age-related mitochondrial dysfunction
in muscle is related to reducedmtDNA abundance. However,
age-associated change in mtDNA abundance seems to be
tissue specific, as several studies have reported no change
in mtDNA abundance with age in other tissues in human
and mouse [159–161]. It is possible that tissue-specific eﬀect
of aging on mtDNA abundance is related to the status of
aerobic activity [156, 158], as aerobic exercise has been
shown to enhancemusclemtDNA abundance in both human
and mouse [162–164]. Increased prevalence of mtDNA
mutations/deletions and decreased mtDNA abundance oﬀer
attractive underlying causes of mitochondrial dysfunction in
aging, which warrants further investigation.
3.3. Mitochondria Malfunction in Age-Associated Human
Diseases. A heterogeneous class of disorders with a broad
spectrum of complex clinical phenotypes has been linked
to mitochondrial defect and oxidative stress [165, 166].
Particularly, mitochondria are thought to play an important
role in the pathogenesis of age-associated neurodegenerative
diseases, such as Alzheimer’s disease, Parkinson’s disease,
and Huntington’s disease. This is not surprising as neurons
are especially sensitive and vulnerable to any abnormality
in mitochondrial function because of their high energy
demand.
Alzheimer’s disease (AD) is the most common form of
dementia and often diagnosed in people over 65 years of age.
AD is characterized by severe neurodegenerative changes,
such as cerebral atrophy, loss of neurons and synapses, and
selective depletion of neurotransmitter systems in cerebral
cortex and certain subcortical region [167]. Mitochondria
are significantly reduced in various types of cells obtained
from patients with AD [168–170]. Dysfunction of mitochon-
drial electron transport chain has also been associated with
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the pathophysiology of AD [170]. The most consistent defect
in mitochondrial electron transport enzymes in AD is a
deficiency in cytochrome c oxidase [171, 172], which leads to
an increase in ROS production, a reduction in energy stores,
and disturbance in energy metabolism [173].
Parkinson’s disease (PD) is the second most common
progressive disorder of the central nervous system, which is
characterized prominently by loss of dopaminergic neurons
in the substantia nigra and formation of intraneuronal
protein aggregates [174]. The finding that exposure to envi-
ronmental toxins, which inhibit mitochondrial respiration
and increase production of ROS, causes loss of dopaminergic
neurons in human and animal models leads to a hypothesis
that oxidative stress and mitochondrial dysfunction are
involved in PD pathogenesis [175]. Consistent with this
notion, a significant decrease in the activity of complex I
of the electron transport chain is observed in the substantia
nigra from PD patients [176]. Furthermore, neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which acts as
an inhibitor of complex I, can induce parkinsonism in
human, monkey, and rodent [177, 178]. Genetic studies
of PINK1 and PARKIN further support the role of mito-
chondrial dysfunction in pathogenesis of PD [179, 180].
Autosomal recessive mutations in PINK1 and PARKIN are
associated with juvenile Parkinsonism [181–183]. Studies in
Drosophila have provided strong evidence that PINK1 and
PARKIN act in the same genetic pathway to control mito-
chondrial morphology in tissues with high energy demand
and requirement of proper mitochondrial function, such as
indirect flight muscle and dopaminergic neurons [184–186].
Consistent with the finding in Drosophila, primary fibrob-
lasts derived from patients with PINK1 mutations show
similar abnormalities in mitochondrial morphology [187].
The morphologic changes of mitochondria can be rescued
by expression of wild-type PARKIN but not pathogenic
PARKIN mutants [187], suggesting that mitochondrial
dynamics plays an important role in PD pathogenesis.
Huntington’s disease (HD) is another hereditary neu-
rodegenerative disorder that aﬀects muscle coordination
and leads to cognitive decline and dementia. HD is caused
by an autosomal dominant mutation in the Huntingtin
(HTT) gene [188]. Morphologic defects of mitochondria,
such as reduced mitochondrial movement and alterations
in mitochondrial ultrastructures, have been observed in
patients with HD or transgenic HD mouse models [189,
190]. In addition, expression of mutant HTT leads to
impaired energy metabolism, abnormal Ca2+ signaling and
mitochondrial membrane potential, and drastic changes
in mitochondrial ultrastructures [191, 192]. Although the
underlying molecular mechanism remains to be determined,
it is recently proposed that mutant HTT conveys its neu-
rotoxicity by evoking defects in mitochondrial dynamics,
mitochondrial fission and fusion, and organelle traﬃcking,
which in turn result in bioenergetic failure and HD-
associated neuronal dysfunction [189].
Mitochondrial dysfunction and increased oxidative dam-
age are often associated with AD, PD, and HD, suggesting
that oxidative stress may play an important role in the
pathophysiology of these diseases [193]. Increased produc-
tion of cellular ROS and oxidative stress have been reported
to induce autophagy, a homeostatic process that enables
cells to degrade cytoplasmic proteins and organelles [194–
197]. The observation of increased autophagy in the brains
of patients with AD, PD, and HD suggests that autophagy
contributes to the pathogenesis of these neurodegenerative
diseases, possibly by causing cell death [170, 198–202].
Consistently, oxidative stress-induced autophagy of accu-
mulated amyloid β-protein in AD causes permeabilization
of lysosomal membrane and leads to neuronal cell death
[203]. Mitochondria damaged by significantly increased
oxidative stress in pyramidal neurons of AD are subjected
to autophagic degradation, ultimately leading to neurode-
generation [204]. Furthermore, overexpression of wild-
type PINK1 increases mitochondrial interconnectivity and
suppresses toxin-induced autophagy, whereas knockdown of
PINK1 expression potentiates mitochondrial fragmentation
and induces autophagy [197], suggesting that induced
autophagy as a consequence of loss of function of PINK1may
contribute to the pathogenesis of PD.
Interestingly, autophagy also serves as a protective mech-
anism in age-related neurodegenerative diseases. Several
studies demonstrate that basal level of autophagy clears the
deleterious protein aggregates that are associated with AD,
PD, and HD [205–207], therefore playing a protective role
in the maintenance of neural cells. For instance, autophagy
is involved in degradation of HTT aggregates [198]. Admin-
istration of rapamycin induces autophagy and enhances the
clearance of mutant HTT, improving cell viability and ame-
liorating HD phenotypes in cell and animal models [208].
Furthermore, PARKIN, whose loss of function mutation
causes early onset PD, has been found to promote autophagy
of depolarized mitochondria [209], suggesting that a failure
to eliminate damaged mitochondria by mutant PARKIN is
responsible for the pathogenesis of PD. It is not entirely clear
why autophagy can exert protective or deleterious eﬀects on
pathogenesis of these neurodegenerative diseases. A better
understanding of autophagy, mitochondrial dysfunction,
and oxidative stress is necessary in order to dissect the
pathogenesis of AD, PD, and HD.
Cancer is considered an age-associated disease, as the
incidence of cancer increases exponentially with age. War-
burg first discovered that cancer cells constitutively metabo-
lize glucose and produce excessive lactic acid even in the pres-
ence of abundant oxygen, a phenomenon named “aerobic
glycolysis” [210]. In contrast, normal cells generate energy
mainly from oxidative breakdown of pyruvate, which is an
end product of glycolysis and is oxidized in mitochondria.
Conversion of glucose to lactate only takes place in the
absence of oxygen (termed “Pasteur eﬀect”) in normal cells.
He hypothesized that defect in mitochondrial respiration in
tumor cells is the cause of cancer, and cancer should be
interpreted as mitochondrial dysfunction [210]. A growing
body of evidence has demonstrated the presence of both
somatic and germline mutations in mtDNA in various types
of human cancers [211–213]. The most direct evidence that
mtDNA mutations may play an important role in neoplas-
tic transformation comes from the study by introducing
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a known pathogenic mtDNA mutation T8993G into the
prostate cancer cell line PC3 through transmitochondrial
cybrids [214]. The T8993G mutation derived from a mito-
chondrial disease patient causes a 70% reduction in ATP
synthase activity and a significant increase in mitochondrial
ROS production [215]. Tumor growth in the T8993Gmutant
cybrids is much faster than that in the wild-type control
cybrids [214]. Moreover, staining of tumor sections confirms
a dramatic increase in ROS production in T8993G mutant
tumors, suggesting that mitochondrial dysfunction and ROS
elevation contribute to tumor progression. Consistent with
this notion, the Sod2+/− mice exhibit increased oxidative
damage and enhanced susceptibility to cancer as compared
to wild-typemice [63]. Collectively, these studies suggest that
mtDNA mutations could contribute to cancer progression
by increasing mitochondrial oxidative damage and changing
cellular energy capacities.
3.4. Mouse Models of Oxidative Stress and Mitochondrial
Dysfunction in Aging. Genetically engineered mouse models
provide great systems to directly dissect the complex relation-
ship between oxidative damage, mitochondrial dysfunction,
and aging. Although it is diﬃcult to manipulate mitochon-
drial genome, genetic engineering of nuclear genes that
are involved in oxidative stress response and mitochondrial
function has been utilized to study mitochondrial biology
and aging.
Mammalian cells scavenge ROS to nontoxic forms
through a sophisticated antioxidant defense that includes su-
peroxide dismutase (SOD), catalase, and glutathione peroxi-
dase. Genetic ablation of SOD2, which encodes a mitochon-
drial manganese SOD (MnSOD), leads to early postnatal
death in mice accompanied by a dilated cardiomyopathy,
metabolic acidosis, accumulation of lipid in liver and
skeletal muscle, increased oxidative damage, and enzymatic
abnormalities in mitochondria [216, 217]. Treatment of
Sod2−/− mice with a synthetic SOD mimetic not only rescues
their mitochondrial defects in the liver, but also dramati-
cally prolongs their survival [218]. Furthermore, heterozy-
gous Sod2+/− mice show evidence of decreased membrane
potential, inhibition of respiration, and rapid accumulation
of mitochondrial oxidative damage [219]. Mitochondrial
oxidative stress induced by partial loss of SOD2 leads to an
increase in proton leak, sensitization of the mitochondrial
permeability transition pore and premature induction of
apoptosis [219]. These studies clearly demonstrate that ROS
generated in mitochondria play an important role in cell
homeostasis and aging.
Conflicting results of the eﬀect of increased SOD2
expression on aging are obtained using diﬀerent SOD2
transgenic mouse strains [220–222]. A transgenic line car-
rying a human SOD2 transgene under the control of a
human β-actin promoter shows protection against hyperoxic
lung injury [220], reduction in mitochondrial superoxide in
hippocampal neurons, and extended lifespan as the result of
increased activity of MnSOD [221]. Another transgenic line
carrying a 13-kb mouse genomic fragment containing SOD2
[223] has a twofold increase in the activity of MnSOD [222].
Such level of SOD2 overexpression does not alter either
lifespan or age-related pathology, even though these mice
exhibit decreased lipid peroxidation, increased resistance
against paraquat-induced oxidative stress, and decreased age-
related decline in mitochondrial ATP production [222]. The
reason behind the diﬀerent outcomes of these two SOD2
transgenic mice on lifespan is not clear, but may be related to
diﬀerent levels of SOD2 expression. The precise role of SOD2
in aging needs further investigation.
An important function of mitochondria is to produce
ATP. Targeting genes involved in ATP production oﬀers a
great opportunity to study the role ofmitochondrial function
in aging. An example is a mouse model with targeted
inactivation of adenine nucleotide translocator (ANT), a
transporter protein that imports ADP and exports ATP from
the mitochondria. Ant1−/− mice exhibit classical physiolog-
ical features of mitochondrial myopathy and hypertrophic
cardiomyopathy in human, as evident of cardiac hypertro-
phy, an increase in succinate dehydrogenase and cytochrome
c oxidase activities, a degeneration of the contractile muscle
fibers, and amassive proliferation of abnormal mitochondria
in skeletal muscle [224]. The increase in mitochondrial
abundance and volume in muscle of Ant1−/− mice is
accompanied by upregulation of genes that are known to
be involved in oxidative phosphorylation [225]. Consistently,
mitochondrial H2O2 production increases in skeletal muscle
and heart of Ant1−/− mice [226]. The Ant1-deficient mouse
model provides strong evidence that a defect in mitochon-
drial energy metabolism can result in pathological disease
[224].
IMMP2L protein is a subunit of a heterodimer complex
of inner mitochondrial membrane peptidase that cleaves
signal peptide from precursor or intermediate polypeptides
after they reach the inner membrane of mitochondria
[227, 228]. Mammalian IMMP2L has two known substrates,
cytochrome c1 and glycerol phosphate dehydrogenase 2,
both of which are involved in superoxide generation [229].
The Immp2l mutant mice have impaired processing of
signal peptide of cytochrome c1 and glycerol phosphate
dehydrogenase 2 [230], and consequently show elevated level
of superoxide ion, hyperpolarization of mitochondria, and
increased oxidative stress in multiple organs. Furthermore,
these Immp2l mutant mice exhibit multiple aging-related
phenotypes, including wasting, sarcopenia, loss of subcuta-
neous fat, kyphosis, and ataxia [101]. These data provide a
strong evidence that mitochondrial dysfunction is a driving
force of accelerated aging.
4. Conclusion
Aging is a complex process involving a multitude of fac-
tors. Many studies have demonstrated that oxidative stress
and mitochondrial dysfunction are two important factors
contributing to the aging process. The importance of mito-
chondrial dynamics in aging is illustrated by its association
with a growing number of age-associated pathogenesis.
A better understanding of response to oxidative stress
and mitochondrial dynamics will lead to new therapeutic
Journal of Signal Transduction 7
approaches for the prevention or amelioration of age-asso-
ciated degenerative diseases.
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